Thromboembolism Trials in Vienna, Austria
Conditions / Thromboembolism / Vienna, Austria
Thromboembolism is a medical condition with active clinical research programs worldwide.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00291330 | Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism | COMPLETED | PHASE3 |
| NCT00168805 | RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery | COMPLETED | PHASE3 |
| NCT00986154 | Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). | COMPLETED | PHASE3 |
| NCT00168818 | Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery | COMPLETED | PHASE3 |
| NCT00329238 | Secondary Prevention of Venous Thrombo Embolism (VTE). | COMPLETED | PHASE3 |
| NCT00353678 | Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2) | COMPLETED | PHASE2 |
| NCT02064439 | Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) | COMPLETED | PHASE3 |
| NCT00206089 | Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events | TERMINATED | PHASE3 |
| NCT00846807 | Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery | COMPLETED | — |
| NCT00847301 | Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery | COMPLETED | — |